SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Value Investing -- Ignore unavailable to you. Want to Upgrade?


To: Lazarus who wrote (66394)2/3/2021 5:38:40 PM
From: Paul Senior  Read Replies (1) | Respond to of 78749
 
Yes, I vaguely remember that name (SPND). I can't remember if I bought and sold and made a profit or if I didn't buy at all. Don't know why I would not have bought -- p/e 2x stocks are almost always automatic buys for me.

I did have that sell opp in SKAS, yes. Shoulda/coulda/dint. And I've forgotten about that dividend. Does make it overall a profitable investment/speculation then.



To: Lazarus who wrote (66394)2/3/2021 8:00:54 PM
From: E_K_S  Read Replies (1) | Respond to of 78749
 
As for USNU -- its been kind of a mutt. nevertheless, good stock structure, no dilution, and with cash on hand and very little dilution --- a good penny stock for speculation.
I still hold this too. As for the company structure it is (to me) much more complicated w/ the Doctor's restructure of this original partnership deal. I likes it the old way and never really understood their new deal other than the Doctor's get more of the FCF off the top to cover expenses.

I have not reviewed their financials (must be over a year now) after they did this restructure. I liked their two office practice (maybe more now) but they still are having trouble growing revenues to the shareholders.

I guess that is better than losses. Not sure if they ever applied for the COVAD business loans but that would allow them to capitalize their fixed assets and may not have to re-pay those loans.

Note: this is from memory and I may have a post down thread where I provided my conclusions and decision to continue to hold.

Link to 10Q and 10K

U.S. Neurosurgical, Inc., a Delaware corporation, was formed in July 1993. The Company owns and operates stereotactic radiosurgery centers, utilizing the Leksell Gamma Knife technology. It currently owns and operates one Gamma Knife centers, one on the premises of Research Medical Center (RMC) in Kansas City, Missouri, and one on the premises of New York University Medical Center (NYU) in New York, New York. The Company's business strategy is to provide cost-effective approaches that allow hospitals, physicians, and patients access to Gamma Knife treatment capability, a high capital cost item. It provides the Gamma Knife to medical facilities on a 'cost per treatment' basis. The Company's business model is to own, or hold an interest in, the Gamma Knife units, and charge the medical facility, where the unit is housed and maintained, based on utilization. Its main target market is medical centers in major health care catchment areas that have physicians experienced with and dedicated to the use of the Gamma Knife. The health care industry, in general, is highly competitive


EKS